Related Experiment Video
Updated: May 2, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
ICDs in end-stage heart failure
Stephen J Pettit1, Susan Browne, Karen J Hogg
1Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, UK.
Insights
Implantable cardioverter defibrillators (ICDs) may offer less benefit in advanced heart failure. Discussing ICD deactivation is crucial but often overlooked, highlighting a gap between best practice and patient care.
Area of Science:
- Cardiology
- Medical Ethics
- Palliative Care
Background:
- Implantable cardioverter defibrillators (ICDs) improve survival in select chronic heart failure patients.
- Prognostic benefits of ICDs may diminish in end-stage heart failure.
- The frequency of futile ICD shocks before death is not well-established.
Purpose of the Study:
- To explore the uncertainty surrounding the futility of ICD therapy in end-stage heart failure.
- To investigate patient and carer perspectives on ICD deactivation.
- To identify barriers to discussing ICD deactivation in clinical practice.
Main Methods:
- Literature review on ICD use in advanced heart failure.
- Analysis of clinical guidelines and expert consensus.
- Qualitative research exploring patient and healthcare professional views (implied).
Main Results:
- The prognostic benefit of ICDs likely decreases as heart failure progresses.
- Decisions regarding ICD futility are best made by individual patients with professional support.
- Routine discussion of ICD deactivation is recommended but infrequently practiced.
Conclusions:
- Patient and carer opinions on ICD deactivation may differ from healthcare professionals' expectations.
- Further research is needed on patient/carer views and interventions to improve deactivation discussions.
- Bridging the gap between recommended practice and actual clinical implementation is essential.
Abstract:
Implantable cardioverter defibrillators (ICDs) reduce mortality in selected patients with chronic heart failure but prognostic benefit is likely to attenuate with progression to end-stage heart failure. The incidence of multiple futile ICD shocks before death is uncertain. Only individual patients, supported by their healthcare professionals, can decide when ICD therapy becomes futile in end-stage heart failure. Despite consensus that ICD deactivation should be routinely discussed, this rarely occurs in clinical practice for many reasons including uncertainty about when to initiate these discussions and reluctance to confront death and dying. Patient and carer opinions about end-stage heart failure and ICD deactivation may not meet professional expectations. Future research should focus on these opinions and examine interventions that bridge the gap between best practice and the reality of current clinical practice.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

